SCNI (Scinai Immunotherapeutics Ltd) Net Profit

SCNI (Scinai Immunotherapeutics Ltd.) - company brandmark

Scinai Immunotherapeutics (SCNI) is poised for growth as it pivots its R&D strategy toward nanobodies for dermatology, a trend supported by the company's annual financial results. The -0.00 level reflects the current magnitude of this metric. Progress in psoriasis treatment and patent protection serve as the primary drivers. Strict cold chain control during drug transportation ensures consistent quality. The price action on the chart warns of overpayment risks during sharp impulsive moves.

SCNI (Scinai Immunotherapeutics) Net Profit history from 02/21/2024 to 11/01/2026

Analytical breakdowns and data insights for company Scinai Immunotherapeutics Ltd. (SCNI)

- price and consensus price forecast:
Stock Quotes BiondVax Pharmaceuticals|SCNI - Analyst Consensus Forecast
- business market valuation indicators:
Market Capitalization BiondVax Pharmaceuticals|SCNI - Real Price to Acquire Entire Company
- book capitalization data:
Accounting Value of a Share Scinai Immunotherapeutics|SCNI - Book Capitalization|Market Capitalization to Book Value scinai.com|SCNI - Aggregate Company Assets
- debt and solvency information:
Total Debt to Equity Ratio Scinai Immunotherapeutics|SCNI - Long-Term Debt to Equity|Short-Term Debt to Equity Ratio Scinai Immunotherapeutics Ltd|SCNI - Company Total Debt|Debts to Book Capitalization BiondVax Pharmaceuticals|SCNI - Company Long-Term Debt|Company Short-Term Indebtedness Scinai Immunotherapeutics|Immediate Liquidity scinai.com
- net income and valuation multiples indicators:
SCNI - Company Net Income
Summary company analysis:Scinai Immunotherapeutics
Core merchandise of Scinai

To assess the fundamental stability of Scinai Immunotherapeutics (SCNI), investors must analyze operational efficiency trends via projected net income on a daily interval. By analyzing the organization's net financial result, one can determine the balance between overpayment risk and growth potential, which is critical for a biotech firm with a unique nanobody platform creating innovative protection against influenza and COVID-19 pandemics.

Main competitors

Net Income argenx BVBA|BNTX (BioNTech SE) - Net Profit|Net Profit Abivax Pharma|Net Income ADMA (ADMA Biologics, Inc.)|PTGX (Protagonist Therapeutics, Inc.) - Final Profit|Net Profit IMVT (Immunovant Corp)|Net Financial Result Kiniksa Corp (KNSA)|GRFS - Company Net Income|adaptivebiotech.com (ADPT) - Net Income|Celldex Therapeutics, Inc. (CLDX) - Company Net Income|Net Income Aurinia Pharmaceuticals Inc|Net Income BCRX|Net Profit Vera Corp|Company Net Income Dianthus Therapeutics (DNTH)|pharvaris.com - Company Profit|Net Profit ABCL (AbCellera Biologics Inc)|Tourmaline Bio Inc (TRML) - Company Net Income|PGEN - Company Net Income|Net Financial Result Pharming Corp PHAR|NKTR: Net Profit|Net Income upstreambio.com|ZBIO (Zenas Biopharma) - Net Profit|Immunome Inc (IMNM) - Net Financial Result|Company Net Income Gossamer Corp (GOSS)|KalVista Corp - Company Profit|Net Profit SEPN (Septerna Inc)|Net Profit pieris.com PVLA|Savara - Net Profit|Net Financial Result Rigel Pharma RIGL|ANAB (AnaptysBio Corp) - Net Income|Astria Corp - Final Profit|ENGN (enGene Holdings Inc.) - Net Profit|rapt.com (RAPT) - Net Financial Result|Company Net Income Aerovate Therapeutics Inc (JBIO)|Net Income Aclaris Therapeutics Inc. ACRS|Company Net Income Kyverna KYTX|TLSA - Net Income|CABA: Net Income|VTYX - Net Profit|Theratechnologies (THTX) - Company Net Income|Company Profit AVTX|Company Net Income Eledon|Company Net Income Agenus, Inc AGEN|Net Income CLYM (Climb Bio Inc)|Profit After Payment of Taxes ZURA|Net Profit ATYR (aTyr Pharma)|Final Profit ADAG|Ikena Oncology, Inc. - Net Profit|Company Net Income Shattuck Labs, Inc.|equilliumbio.com (EQ) - Company Net Income|Connect Biopharma Holdings Limited - Final Profit|IMUX (Immunic Therapeutics) - Net Profit|Net Profit Atara Biotherapeutics Inc|Company Net Income InflaRx N.V. (IFRX)|XFOR: Profit After Tax|Net Profit ACET (Adicet Bio, Inc.)|Celularity Inc (CELU) - Company Net Income|INMB: Net Income|BRNS - Net Profit|KZR (Kezar Life Sciences, Inc) - Net Income|SABS: Profit After Payment of Taxes|AKTX (Akari Therapeutics) - Net Profit|Enlivex Therapeutics, Ltd. (ENLV) - Net Financial Result|Net Profit QTTB|Net Income GeoVax Labs GOVX|Company Net Income Edesa EDSA|Net Financial Result iBio Corporation (IBIO)|CARM - Company Net Income|Net Financial Result xtlbio.com XTLB|BOLT: Net Profit|Net Income HCW Biologics|Company Net Income Aptevo Therapeutics, Inc.|Company Profit AIM (aimimmuno.com)|Net Profit ADTX|Net Financial Result gribio.com|Company Net Income XORTX Therapeutics XRTX|HIND (Vyome Holdings Inc.) - Profit After Tax|Revelation Bio - Net Profit|Final Profit INDP (Indaptus Corp)|CALI: Net Profit|Affimed N.V. (AFMD) - Net Profit|Company Net Income Allakos Inc|HOOK: Final Profit|Company Net Income IGM Biosciences, Inc. (IGMS)|Net Income iTeos Pharma ITOS|Net Profit OCEA (Ocean Biomedical, Inc.)|Net Profit tcbiopharm.com TCBP|THRD: Net Income